Clinical Trials in Edinburgh, UK

Clinical Trials in Edinburgh

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a UK site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full UK registry across all sponsors is far larger. UK studies may also be registered separately on ISRCTN.

Status

Study

Lead sponsor

Phase

Enrol

UK sites

Start

Active, closed

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

NCT04494425Advanced or Metastatic Breast Cancer

AstraZeneca

Phase 3

866

Cambridge, Cardiff, Edinburgh, Guildford, Leeds, London, Manchester, Northwood

2020-07-24

Active, closed

Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

NCT03997123Triple Negative Breast Neoplasms

AstraZeneca

Phase 3

923

Edinburgh, London, Sheffield, Surrey, York

2019-06-25

Active, closed

Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC

NCT03732677Muscle Invasive Bladder Cancer

AstraZeneca

Phase 3

1,063

Edinburgh, London, Metropolitan Borough of Wirral, Nottingham, Sheffield

2018-11-16

Active, closed

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

NCT03330847Metastatic Triple Negative Breast Cancer

AstraZeneca

Phase 2

273

Aberdeen, Bristol, Cardiff, Durham, Edinburgh, Leicester, London, Manchester

2018-03-07

Active, closed

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer

NCT02032823Breast Cancer

AstraZeneca

Phase 3

1,837

Belfast, Birmingham, Bournemouth, Bristol, Cambridge, Cardiff, Dudley, Edinburgh

2014-04-22

Active, closed

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

NCT01874353Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy

AstraZeneca

Phase 3

327

Birmingham, Cambridge, Coventry, Edinburgh, London, Manchester, Sutton

2013-09-03

Active, closed

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.

NCT01844986Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation

AstraZeneca

Phase 3

450

Birmingham, Cambridge, Coventry, Edinburgh, London, Sutton

2013-08-26

Active, closed

Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

NCT01081951Ovarian Cancer

AstraZeneca

Phase 2

162

Birmingham, Coventry, Edinburgh

2010-02-04

Active, closed

Phase I Comparative Bioavailability Study

NCT00777582Solid Tumors

AstraZeneca

Phase 1

197

Edinburgh, London, Manchester, Newcastle upon Tyne, Northwood, Oxford, Sutton

2008-10-27

Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a UK investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 19 September 2026. https://priyalifescience.com/clinical-trials-uk/city/edinburgh

Query this register directly

GET /api/trials?country=uk&status=recruiting&format=json Try it now →